- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02067650
Ultrasound Findings of Finger, Wrist and Knee Joints in Mucopolysaccharidosis
January 23, 2018 updated by: Johannes Roth, Children's Hospital of Eastern Ontario
Hardly any imaging studies specifically addressing the articular and periarticular structures in MPS patients are available at this point.
The investigators propose to do for the first time a pilot study using musculoskeletal ultrasound in patients with various types of MPS.
Study Overview
Study Type
Observational
Enrollment (Actual)
18
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H8L1
- Children's Hospital of Eastern Ontario
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 99 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with MPS I and IV
Description
Inclusion Criteria
- Diagnosis of Mucopolysaccharidosis
- Ability to collaborate with the ultrasound assessment
- Written informed consent from parents and patients over 14 years of age, assent from children 7 to 14 years
Exclusion Criteria
- Inability to collaborate with the ultrasound assessment
- Acute trauma to a joint that will be assessed in the 3 months preceding the study
- Coexistence of other pathology that is known to affect the respective joints
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Power Doppler
Time Frame: one time exam
|
The primary objective is to determine whether patients with various types of MPS and at various stages of the disease exhibit abnormalities of the finger, wrist and knee joints as assessed by grey scale and Power Doppler ultrasonography.
|
one time exam
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ultrasound scanning technique
Time Frame: one time scan
|
To determine the optimal ultrasound scanning technique for MPS patients given the potentially advanced joint contractures
|
one time scan
|
|
Findings of synovitis or tenosynovitis
Time Frame: one time scan
|
To determine whether there are ultrasound findings indicative of synovitis or tenosynovitis
|
one time scan
|
|
Differences between MPS I and IV
Time Frame: one time scan
|
To determine whether differences exist between MPS I and MPS IV
|
one time scan
|
|
Differences between ERT and BMT
Time Frame: one time scan
|
To determine whether differences exist between patients with or without Enzyme Replacement Therapy (ERT) or Bone Marrow Transplants
|
one time scan
|
|
Differences between severe and attenuated phenotypes
Time Frame: one time scan
|
To determine whether differences exist between severe and attenuated phenotypes
|
one time scan
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Johannes Roth, MD, Children's Hospital of Eastern Ontario
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2013
Primary Completion (Actual)
March 1, 2016
Study Completion (Actual)
December 1, 2016
Study Registration Dates
First Submitted
August 13, 2013
First Submitted That Met QC Criteria
February 19, 2014
First Posted (Estimate)
February 20, 2014
Study Record Updates
Last Update Posted (Actual)
January 24, 2018
Last Update Submitted That Met QC Criteria
January 23, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MPSUS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MPS I
-
Sigilon Therapeutics, Inc.WithdrawnMPS I | MPS1-S | MPS1-HSBrazil, United Kingdom
-
Children's Hospital of Orange CountyNational Heart, Lung, and Blood Institute (NHLBI)RecruitingMPS IVA | MPS IV A | MPS - Mucopolysaccharidosis | MPS IUnited States
-
University of ExeterThe University of Texas Medical Branch, Galveston; Wageningen UniversityCompletedVitamin D Effects on MPS | Placebo Effects on MPSUnited Kingdom
-
University of ChicagoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedKrabbe Disease | Mucopolysaccharidosis Type II (MPS II) | Mucopolysaccharidosis Type I (MPS I) | Mucopolysaccharidosis Type III (MPS III) | Mucopolysaccharidosis Type VI (MPS VI)United States
-
Mackay Memorial HospitalSanofi Taiwan Co. LtdRecruiting
-
Genzyme, a Sanofi CompanyCompletedMucopolysaccharidosis I (MPS I)Sweden, Portugal, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Egypt, France, Germany, Hong Kong, India, Indonesia, Ireland, Italy, Japan, Kuwait, Lebanon, Malaysia, Netherlands, Pakistan, Philippine... and more
-
Sangamo TherapeuticsTerminated
-
REGENXBIO Inc.SuspendedHurler Syndrome | Hurler-Scheie Syndrome | Mucopolysaccharidosis Type I (MPS I)Brazil, United States
-
Masonic Cancer Center, University of MinnesotaWithdrawnMucopolysaccharidosis Type IH | Mucopolysaccharidosis Type IH (MPS IH, Hurler Syndrome) | MPS IH, Hurler Syndrome
-
Masonic Cancer Center, University of MinnesotaTerminatedHurler Syndrome | Mucopolysaccharidosis Type IH | MPS IUnited States